Intellectual property

With several obtained and pending patents, Opiant is positioned to become a leader in the substance use, addictive, and eating disorders treatment markets. Opiant has the global rights for the use of a novel formulation that could be used in its opioid antagonist nasal spray technology. In the U.S. and Europe, Opiant has patents issued for the use of nasal naloxone for the treatment of all eating disorders. In the U.S. and Europe, Opiant has patents pending for its nasal spray treatment for opioid overdose.